Combination of Novel Therapies for CKD Comorbid Depression
Phase 2
201
about 6.5 years
18+
4 sites in NY, TX, WA
What this study is about
This trial is testing if combining behavioral therapy, bupropion, and clinical management with a treatment improves outcomes in people with chronic kidney disease (CKD) who also have depression. The goal is to find better ways to treat depression in this specific patient population.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Clinical Management
- 2.Participate in Behavioral activation therapy
- 3.Take Bupropion
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bupropion
Secondary: Fatigue assessed by the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scale, High sensitivity C-reactive protein, Serious adverse events, Serious adverse events with monotherapy, Sleep assessed by the Insomnia Severity Index (ISI)
Psychiatry / Mental Health, Renal